Table 5.
Association of TLR7 polymorphisms with COVID-19 outcomes in men.
| Polymorphisms | Severe |
Critical |
Deceased |
||||||
|---|---|---|---|---|---|---|---|---|---|
| ORa |
95% CI |
P |
ORa |
95% CI |
P |
ORa |
95% CI |
P |
|
| TLR7 | |||||||||
| rs179008 | |||||||||
| A | Reference | Reference | Reference | ||||||
| T | 1.06 | 0.63–1.82 | 0.82 | 0.66 | 0.36–1.20 | 0.17 | 0.77 | 0.37–1.59 | 0.48 |
| rs179009 | |||||||||
| A | Reference | Reference | Reference | ||||||
| G | 0.78 | 0.49–1.22 | 0.28 | 0.59 | 0.35–98 | 0.04 | 0.99 | 0.54–1.82 | 0.99 |
| rs3853839 | |||||||||
| C | Reference | Reference | Reference | ||||||
| G | 1.22 | 0.76–1.98 | 0.4 | 2.49 | 1.43–4.32 | 0.001 | 1.42 | 0.74–2.7 | 0.28 |
| rs2302267 | |||||||||
| T | Reference | Reference | Reference | ||||||
| G | 0.79 | 0.37–1.68 | 0.55 | 1.72 | 0.80–3.68 | 0.15 | 0.88 | 0.33–2.34 | 0.82 |
a
Adjusted for age, hypertension, type 2 diabetes, and obesity.